Edwards Lifesciences and DexCom to Develop Continuous Glucose Monitoring Products for Hospital Market

IRVINE, CA and SAN DIEGO, CA, Nov 10 (MARKET WIRE) --
Edwards Lifesciences Corporation (NYSE: EW), a global leader in the
monitoring of critically ill patients, and DexCom, Inc. (NASDAQ: DXCM), a
developer and marketer of home-based continuous glucose monitoring
systems for patients with diabetes, have entered into a definitive
collaboration agreement to develop products for continuously monitoring
blood glucose levels in patients hospitalized for a variety of
conditions. The agreement provides Edwards with an exclusive license to
all of DexCom's applicable intellectual property.

Under the terms of the agreement, Edwards will pay DexCom an upfront
licensing and collaboration fee of $13 million in cash, resulting in a
nonrecurring charge for Edwards in the fourth quarter of 2008. Edwards
will also pay up to $24 million over the next three years in product
development costs and regulatory approval milestones. Edwards believes
that the R&D component of these payments will be approximately $7 million
in 2009. In addition, DexCom will receive either a profit-sharing payment
of ten percent or royalty of up to six percent of commercial sales.
Edwards will be responsible for global sales and marketing, which is
expected to begin in 2010, and DexCom will be responsible for initial
manufacturing.

"There is growing evidence that closely monitoring glucose levels in
critically ill patients can positively impact patient care and outcomes,
however, existing intermittent monitoring methods do not make this
practical for hospitals to employ on a widespread basis. Edwards is
excited to work with DexCom to develop technology that allows clinicians
to better maintain tight glycemic control of patients in an operating
room or intensive care unit setting," said Carlyn Solomon, Edwards'
corporate vice president, critical care and vascular. "This collaboration
combines DexCom's diagnostic testing and sensor technology experience
with Edwards' leadership in monitoring critically ill patients and
knowledge of the critical care environment."

"DexCom looks forward to working with Edwards to further develop this
continuous glucose sensing technology for use in a hospital setting," said
Terrance H. Gregg, DexCom's president and CEO. "We are confident in the
ability of this technology to provide new opportunities to serve a large
number of critically ill diabetic and non-diabetic patients. We believe
that collaborating with Edwards can extend our portfolio of pioneering
glucose monitoring technologies by offering clinicians a device designed
to meet the needs of a critical care patient."

Tight glycemic control is often implemented in a hospital's critical care
setting to stabilize and maintain a patient's blood glucose levels within
a specified range. Studies show that when a patient's blood glucose level
is high for prolonged periods, recovery from surgery takes longer and the
risk of infection increases. Currently, tight glycemic control is
achieved by obtaining samples every 30 to 60 minutes, however this
testing practice may be too intermittent and cumbersome. The development
of a method for continuous glucose monitoring via an indwelling sensor
would enable clinicians to be more effective in implementing tight
glycemic control and provide for better accuracy in monitoring and
controlling patients' blood glucose levels.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves
and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards
treats advanced cardiovascular disease with its market-leading heart valve
therapies, and critical care and vascular technologies. In 2008, Edwards
celebrates 50 years of partnering with clinicians to develop life-saving
innovations. The company's global brands, which are sold in approximately
100 countries, include CardioVations, Carpentier-Edwards,
Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz.
Additional company information can be found at http://www.edwards.com.

About DexCom

DexCom, Inc., headquartered in San Diego, Calif., is an innovative company
focused on pioneering ground-breaking continuous glucose monitoring
technologies for improving the health and lives of people with diabetes.
DexCom has developed the SEVEN System, a Continuous Glucose Monitoring
(CGM) device, which includes the SEVEN Sensor, Transmitter, and Receiver.
Published clinical evidence continues to support the value of CGM and
demonstrates dramatic improvements in glucose control. Additional company
information can be found at http://www.dexcom.com.

This news release includes forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These forward-looking statements
include, but are not limited to, the ability of this transaction to
generate sales and impact earnings and, more generally, the ability to
consummate targeted technology investments and acquisitions.
Forward-looking statements are based on estimates and assumptions made by
management of the company and are believed to be reasonable, though they
are inherently uncertain and difficult to predict.

Forward-looking statements involve risks and uncertainties that could
cause actual results or experience to differ materially from that
expressed or implied by the forward-looking statements. Factors that
could cause actual results or experience to differ materially from that
expressed or implied by the forward-looking statements are detailed in
the company's filings with the Securities and Exchange Commission
including its Annual Report on Form 10-K for the year ended December 31,
2007.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards
Lifesciences, the stylized E logo, Carpentier-Edwards, Cosgrove-Edwards,
FloTrac, Fogarty, Magna, PERIMOUNT Magna and Swan-Ganz are trademarks of
Edwards Lifesciences Corporation and are registered in the United States
Patent and Trademark Office. CardioVations is a trademark of Edwards
Lifesciences AG and is registered in the United States Patent and
Trademark Office.

DexCom and SEVEN are trademarks of DexCom, Inc.

Edwards Lifesciences

Media Contact:
Sarah Huoh
949-250-5070

Investor Contact:
David K. Erickson
949-250-6826

DexCom

Media/Investor Contact:
Steven R. Pacelli
858-200-0200

Copyright 2008, Market Wire, All rights reserved.

-0-